In the VICTORIA trial, VERQUVO demonstrated an adverse event profile similar to placebo<\/strong><\/h1><\/div>\n\n\n\n<\/div>\n\n\n\nVERQUVO is well tolerated by patients following a HF hospitalization or use of outpatient IV diuretics<\/strong><\/h3><\/div>\n\n\n\n<\/div>\n\n\n\nThe adverse drug reactions occurring more commonly with VERQUVO than placebo and in \u22655% of patients treated with VERQUVO in VICTORIA<\/strong><\/p>\n\n\n\n<\/div>\n\n\n\n\n<\/div>![\"Adverse](\"https:\/\/www.merckconnect.com\/verquvo\/wp-content\/uploads\/sites\/67\/2022\/12\/tolerability-table-desktop.png\")
<\/picture><\/p><\/figcaption><\/figure><\/div>\n\n\n\n
<\/div>\n\n\n\n7.0% of patients taking VERQUVO discontinued due to AEs1<\/sup><\/strong><\/h2><\/div>AEs = adverse events.<\/p><\/div><\/div>![\"Percentage](\"https:\/\/www.merckconnect.com\/verquvo\/wp-content\/uploads\/sites\/67\/2022\/12\/callout_safety.png\")
<\/picture><\/p><\/figcaption><\/figure><\/div>\n\n\n\n
<\/div>\n\n\n\nTreatment initiation with VERQUVO 5 mg once daily in VELOCITY was similarly tolerated as treatment initiation of 2.5 mg once daily in the VICTORIA study.<\/strong><\/p><\/div><\/div>\n\n\n\n<\/div>\n\n\n\na<\/sup>Background therapy included beta blocker, ACE inhibitor, ARB, MRA, ARNI, and\/or SGLT2 inhibitor.<\/p>\n\n\n\n<\/div>\n\n\n\nStudy designs<\/strong><\/h3><\/div>\n\n\n\nVICTORIA<\/strong> was a Phase 3, randomized, parallel-group, placebo-controlled, double-blind, event-driven, multicenter trial comparing VERQUVO to placebo when added to background HF therapy in 5,050 adult patients with NYHA class II-IV chronic HF and LVEF <45% following a worsening HF event (defined as HF hospitalization within 6 months before randomization or use of outpatient IV diuretics for HF within 3 months before randomization). Patients were treated up to the target maintenance dose of VERQUVO 10 mg once daily or matching placebo. The primary endpoint was a composite of time to first event of CV death or HF hospitalization.1<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\nVELOCITY<\/strong> was a Phase 2b, 2-week, open-label, single-arm, multinational prospective trial evaluated the safety and tolerability of VERQUVO 5 mg once daily as a starting dose. The trial enrolled 106 adult patients aged \u226518 years with chronic heart failure and a left ventricular ejection fraction <45%, New York Heart Association class II\u2013IV symptoms, and systolic blood pressure \u2265100mmHg at screening and Visit 1. Study participants with or without worsening heart failure on background guideline-directed medical therapy for heart failure underwent screening for eligibility. Eligible patients returned 2 weeks later for Visit 1. At this Visit 1, VERQUVO 5 mg daily was initiated and continued for 2 weeks as tolerated until the final visit (Visit 2). The primary endpoint was to assess the tolerability of a 5 mg VERQUVO starting dose, defined as completing the 2-week course with no more than a 1-day interruption and without moderate-to-severe symptomatic hypotension.2<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\nDefinitions:<\/strong><\/h3><\/div>\n\n\n\nACE = angiotensin-converting enzyme; AEs = adverse events; ARB = angiotensin II receptor blocker; ARNI = combination of an angiotensin receptor and neprilysin inhibitor; CV = cardiovascular; HF = heart failure; IV = intravenous; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association; SGLT2 = sodium glucose co-transporter 2; VICTORIA = Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.<\/p>\n\n\n\n
<\/div>\n\n\n\nReference:<\/strong><\/h3><\/div>\n\n\n\n\n- Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med.<\/em> 2020;382(20):1883-1893.<\/li>
- Greene SJ, Corda S, McMullan CJ, et al, on behalf of the VELOCITY investigators. Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: The VELOCITY study. Eur J Heart Fail<\/em>. 2025(27):2837-2840. https:\/\/doi.org\/10.1002\/ejhf.3699<\/li><\/ol><\/div>\n\n\n\n\n<\/span><\/div>
VERQUVO is well tolerated by patients following a HF hospitalization or use of outpatient IV diuretics<\/strong><\/h3><\/div>\n\n\n\n<\/div>\n\n\n\nThe adverse drug reactions occurring more commonly with VERQUVO than placebo and in \u22655% of patients treated with VERQUVO in VICTORIA<\/strong><\/p>\n\n\n\n<\/div>\n\n\n\n\n<\/div><\/picture><\/p><\/figcaption><\/figure><\/div>\n\n\n\n
<\/div>\n\n\n\n7.0% of patients taking VERQUVO discontinued due to AEs1<\/sup><\/strong><\/h2><\/div>AEs = adverse events.<\/p><\/div><\/div><\/picture><\/p><\/figcaption><\/figure><\/div>\n\n\n\n
<\/div>\n\n\n\nTreatment initiation with VERQUVO 5 mg once daily in VELOCITY was similarly tolerated as treatment initiation of 2.5 mg once daily in the VICTORIA study.<\/strong><\/p><\/div><\/div>\n\n\n\n<\/div>\n\n\n\na<\/sup>Background therapy included beta blocker, ACE inhibitor, ARB, MRA, ARNI, and\/or SGLT2 inhibitor.<\/p>\n\n\n\n<\/div>\n\n\n\nStudy designs<\/strong><\/h3><\/div>\n\n\n\nVICTORIA<\/strong> was a Phase 3, randomized, parallel-group, placebo-controlled, double-blind, event-driven, multicenter trial comparing VERQUVO to placebo when added to background HF therapy in 5,050 adult patients with NYHA class II-IV chronic HF and LVEF <45% following a worsening HF event (defined as HF hospitalization within 6 months before randomization or use of outpatient IV diuretics for HF within 3 months before randomization). Patients were treated up to the target maintenance dose of VERQUVO 10 mg once daily or matching placebo. The primary endpoint was a composite of time to first event of CV death or HF hospitalization.1<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\nVELOCITY<\/strong> was a Phase 2b, 2-week, open-label, single-arm, multinational prospective trial evaluated the safety and tolerability of VERQUVO 5 mg once daily as a starting dose. The trial enrolled 106 adult patients aged \u226518 years with chronic heart failure and a left ventricular ejection fraction <45%, New York Heart Association class II\u2013IV symptoms, and systolic blood pressure \u2265100mmHg at screening and Visit 1. Study participants with or without worsening heart failure on background guideline-directed medical therapy for heart failure underwent screening for eligibility. Eligible patients returned 2 weeks later for Visit 1. At this Visit 1, VERQUVO 5 mg daily was initiated and continued for 2 weeks as tolerated until the final visit (Visit 2). The primary endpoint was to assess the tolerability of a 5 mg VERQUVO starting dose, defined as completing the 2-week course with no more than a 1-day interruption and without moderate-to-severe symptomatic hypotension.2<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\nDefinitions:<\/strong><\/h3><\/div>\n\n\n\nACE = angiotensin-converting enzyme; AEs = adverse events; ARB = angiotensin II receptor blocker; ARNI = combination of an angiotensin receptor and neprilysin inhibitor; CV = cardiovascular; HF = heart failure; IV = intravenous; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association; SGLT2 = sodium glucose co-transporter 2; VICTORIA = Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.<\/p>\n\n\n\n
<\/div>\n\n\n\nReference:<\/strong><\/h3><\/div>\n\n\n\n\n- Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med.<\/em> 2020;382(20):1883-1893.<\/li>
- Greene SJ, Corda S, McMullan CJ, et al, on behalf of the VELOCITY investigators. Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: The VELOCITY study. Eur J Heart Fail<\/em>. 2025(27):2837-2840. https:\/\/doi.org\/10.1002\/ejhf.3699<\/li><\/ol><\/div>\n\n\n\n\n<\/span><\/div>
The adverse drug reactions occurring more commonly with VERQUVO than placebo and in \u22655% of patients treated with VERQUVO in VICTORIA<\/strong><\/p>\n\n\n\n <\/p><\/figcaption><\/figure><\/div>\n\n\n\n AEs = adverse events.<\/p><\/div><\/div> <\/p><\/figcaption><\/figure><\/div>\n\n\n\n Treatment initiation with VERQUVO 5 mg once daily in VELOCITY was similarly tolerated as treatment initiation of 2.5 mg once daily in the VICTORIA study.<\/strong><\/p><\/div><\/div>\n\n\n\n a<\/sup>Background therapy included beta blocker, ACE inhibitor, ARB, MRA, ARNI, and\/or SGLT2 inhibitor.<\/p>\n\n\n\n VICTORIA<\/strong> was a Phase 3, randomized, parallel-group, placebo-controlled, double-blind, event-driven, multicenter trial comparing VERQUVO to placebo when added to background HF therapy in 5,050 adult patients with NYHA class II-IV chronic HF and LVEF <45% following a worsening HF event (defined as HF hospitalization within 6 months before randomization or use of outpatient IV diuretics for HF within 3 months before randomization). Patients were treated up to the target maintenance dose of VERQUVO 10 mg once daily or matching placebo. The primary endpoint was a composite of time to first event of CV death or HF hospitalization.1<\/sup><\/p>\n\n\n\n VELOCITY<\/strong> was a Phase 2b, 2-week, open-label, single-arm, multinational prospective trial evaluated the safety and tolerability of VERQUVO 5 mg once daily as a starting dose. The trial enrolled 106 adult patients aged \u226518 years with chronic heart failure and a left ventricular ejection fraction <45%, New York Heart Association class II\u2013IV symptoms, and systolic blood pressure \u2265100mmHg at screening and Visit 1. Study participants with or without worsening heart failure on background guideline-directed medical therapy for heart failure underwent screening for eligibility. Eligible patients returned 2 weeks later for Visit 1. At this Visit 1, VERQUVO 5 mg daily was initiated and continued for 2 weeks as tolerated until the final visit (Visit 2). The primary endpoint was to assess the tolerability of a 5 mg VERQUVO starting dose, defined as completing the 2-week course with no more than a 1-day interruption and without moderate-to-severe symptomatic hypotension.2<\/sup><\/p>\n\n\n\n ACE = angiotensin-converting enzyme; AEs = adverse events; ARB = angiotensin II receptor blocker; ARNI = combination of an angiotensin receptor and neprilysin inhibitor; CV = cardiovascular; HF = heart failure; IV = intravenous; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association; SGLT2 = sodium glucose co-transporter 2; VICTORIA = Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.<\/p>\n\n\n\n<\/picture>7.0% of patients taking VERQUVO discontinued due to AEs1<\/sup><\/strong><\/h2><\/div>
<\/picture>Study designs<\/strong><\/h3><\/div>\n\n\n\n
Definitions:<\/strong><\/h3><\/div>\n\n\n\n
Reference:<\/strong><\/h3><\/div>\n\n\n\n\n